Arş. Gör. ALPER COŞKUN

1. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.

International Journal of Cancer , cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)

2. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

Tunbekici S., Sahin G., Yuksel H. C., Acar C., Akın I., Aslanhan H., et al.

International Journal of Cancer , cilt.158, sa.6, ss.1703-1712, 2026 (SCI-Expanded, Scopus)

3. Association of IMP3 and CD10 Expression with Clinicopathological Features and Outcomes in Phyllodes Tumors: A Retrospective Single-Center Study

ODABAŞI BÜKÜN H., ÇUBUKÇU E., DELİGÖNÜL A., ŞAHİN A. B., Coşkun A., AKIN G., et al.

Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)

4. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

Tunbekici S., Sahin G., Yuksel H. C., Acar C., Akın I., Aslanhan H., et al.

Discover Oncology , cilt.16, sa.1, 2025 (SCI-Expanded, Scopus)

5. Meme Kanserinde Psikososyal Yükün Kapsamlı Değerlendirilmesi: Türkiye’de Çok Merkezli Kesitsel Bir Çalışma

Gökmen İ., Divriklioğlu D., ozcan e., Çakıcı V., Coşkun A., DEMİR N., et al.

Namık Kemal Tıp Dergisi , cilt.13, sa.3, ss.231-245, 2025 (ESCI, TRDizin)

6. Biologically Informed Decision-Making for PMRT in pT3N0M0 Luminal Breast Cancers (Protocol MF22-02): International Multicenter Real-World Data

Soran A., Gultekin M. B., Venkatesulu B. P., Barry P. N., King C., Bhargava R., et al.

Clinical Breast Cancer , cilt.25, sa.7, 2025 (SCI-Expanded, Scopus)

7. Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast

Sali S., SALİ M., Caner B., Ocak B., ÇOBAN E., COŞKUN A., et al.

Oncologist , cilt.30, sa.8, 2025 (SCI-Expanded, Scopus)

8. Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary Bladder: A Propensity Score-Matched Analysis

Coskun A., ŞAHİN A. B., KABUL S., Celik M. A., SALİ M., ÖZÇELİK E. E., et al.

Current Oncology , cilt.32, sa.7, 2025 (SCI-Expanded, Scopus)

9. Prediction of Cardiac Arrhythmias in Cancer Patients Treated with Immune Checkpoint Inhibitors Using Electrocardiogram

Coskun A., Celebi Coskun E., ŞAHİN A. B., Levent F., Coban E., Koca F., et al.

Diagnostics , cilt.15, sa.10, 2025 (SCI-Expanded, Scopus)

10. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., Sahin T. K., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)

11. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

TÜNBEKİCİ S., YÜKSEL H. Ç., ACAR C., Sahin G., Orman S., Majidova N., et al.

CANCERS , cilt.17, sa.1, 2025 (SCI-Expanded, Scopus)

12. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Beypınar İ., Demir H., YASLIKAYA Ş., KÖŞECİ T., Demir B., Çolak G., et al.

Breast Cancer Research and Treatment , cilt.208, sa.3, ss.597-604, 2024 (SCI-Expanded, Scopus)

13. Salmonella carriage and change in serovar distribution in broiler giblets at slaughterhouse level in Turkiye: first report using ISO 6579-1:2017 and ISO 6579-3:2014

Akgun Z., Coşkun A., Cetin E., Temelli S., Eyigör A. G.

Poultry Science , cilt.103, sa.7, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Left ventricular global longitudinal strain in patients treated with immune checkpoint inhibitors

Coskun E. C., COŞKUN A., ŞAHİN A. B., Levent F., ÇOBAN E., Koca F., et al.

FRONTIERS IN ONCOLOGY , cilt.14, 2024 (SCI-Expanded, Scopus)

Arş. Gör. ALPER COŞKUN

Yayınlar & Eserler

1. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

2. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

3. Association of IMP3 and CD10 Expression with Clinicopathological Features and Outcomes in Phyllodes Tumors: A Retrospective Single-Center Study

4. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

5. Meme Kanserinde Psikososyal Yükün Kapsamlı Değerlendirilmesi: Türkiye’de Çok Merkezli Kesitsel Bir Çalışma

6. Biologically Informed Decision-Making for PMRT in pT3N0M0 Luminal Breast Cancers (Protocol MF22-02): International Multicenter Real-World Data

7. Primary neuroendocrine tumors of the breast according to the WHO 2019 classification; real life experiences of rare tumor types of the breast

8. Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary Bladder: A Propensity Score-Matched Analysis

9. Prediction of Cardiac Arrhythmias in Cancer Patients Treated with Immune Checkpoint Inhibitors Using Electrocardiogram

10. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

11. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

12. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

13. Salmonella carriage and change in serovar distribution in broiler giblets at slaughterhouse level in Turkiye: first report using ISO 6579-1:2017 and ISO 6579-3:2014

14. Left ventricular global longitudinal strain in patients treated with immune checkpoint inhibitors

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)